Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bertz

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|January 1, 1985
[Epidemiology of malignant melanoma of the skin: an international comparison]C E Orfanos, C Garbe, J Bertz
Dermatologica|January 1, 1991
Malignant melanoma in southern Germany: different predictive value of risk factors for melanoma subtypesJ Weiss, J Bertz, E G Jung
Zeitschrift Fur Hautkrankheiten|December 15, 1986
[Malignant melanoma: increase in incidence and mortality in West Germany]C Garbe, J Bertz, C E Orfanos
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|September 19, 2001
[Cancer incidence estimates for Germany via log-linear models]J Haberland, J Bertz, B Görsch, et al.
Clinical Pharmacokinetics|November 13, 1998
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agentsA Hsu, G R Granneman, R J Bertz
Hospitals|October 16, 1976
Viewing the hospital as a working environmentE J Bertz, R diMonda, J G Sprague
Neuropharmacology|September 1, 1995
Effect of neuroactive steroids on [3H]flumazenil binding to the GABAA receptor complex in vitroR J Bertz, I J Reynolds, P D Kroboth
Clinical Pharmacokinetics|July 17, 2015
Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug InteractionsTimothy Eley, Tushar Garimella, Wenying Li, et al.
Clinical Pharmacology in Drug Development|March 7, 2017
Asunaprevir: An HCV Protease Inhibitor With Preferential Liver DistributionTimothy Eley, Tushar Garimella, Wenying Li, et al.
Health Law Vigil|June 4, 1982
HCFA issues NPRM on Medicare/Medicaid certification processE A Pryga, E J Bertz, L A Tomaselli
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|January 1, 1985
[Epidemiology of malignant melanoma of the skin: an international comparison]C E Orfanos, C Garbe, J Bertz
Dermatologica|January 1, 1991
Malignant melanoma in southern Germany: different predictive value of risk factors for melanoma subtypesJ Weiss, J Bertz, E G Jung
Zeitschrift Fur Hautkrankheiten|December 15, 1986
[Malignant melanoma: increase in incidence and mortality in West Germany]C Garbe, J Bertz, C E Orfanos
Gesundheitswesen (Bundesverband Der Arzte Des Offentlichen Gesundheitsdienstes (Germany))|September 19, 2001
[Cancer incidence estimates for Germany via log-linear models]J Haberland, J Bertz, B Görsch, et al.
Clinical Pharmacokinetics|November 13, 1998
Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agentsA Hsu, G R Granneman, R J Bertz
Hospitals|October 16, 1976
Viewing the hospital as a working environmentE J Bertz, R diMonda, J G Sprague
Neuropharmacology|September 1, 1995
Effect of neuroactive steroids on [3H]flumazenil binding to the GABAA receptor complex in vitroR J Bertz, I J Reynolds, P D Kroboth
Clinical Pharmacokinetics|July 17, 2015
Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug InteractionsTimothy Eley, Tushar Garimella, Wenying Li, et al.
Clinical Pharmacology in Drug Development|March 7, 2017
Asunaprevir: An HCV Protease Inhibitor With Preferential Liver DistributionTimothy Eley, Tushar Garimella, Wenying Li, et al.
Health Law Vigil|June 4, 1982
HCFA issues NPRM on Medicare/Medicaid certification processE A Pryga, E J Bertz, L A Tomaselli
Pageof 6